Search

Your search keyword '"Aldoss, Ibrahim"' showing total 1,211 results
Start Over Author "Aldoss, Ibrahim"
1,211 results on '"Aldoss, Ibrahim"'

3. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Author

Desai, Amrita, Samara, Yazeed, Yang, Dongyun, Ball, Brian, Braun, Adam, Koller, Paul, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet, Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Al Malki, Monzr M., Artz, Andrew, Becker, Pamela, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Curtin, Peter, Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

4. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron D., Stein, Eytan M., Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos Perez, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., Stone, Richard M., Garciaz, Sylvain, Ball, Brian, and Stahl, Maximilian

Published
2024
Full Text
View/download PDF

6. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

7. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

Author

ALBERT, DANIEL H, GOODWIN, NEAL C, DAVIES, ANGELA M, ROWE, JENNY, FEUER, GEROLD, BOYIADZIS, MICHAEL, DORRITIE, KATHLEEN A, MANCINI, MARIA, GANDOUR-EDWARDS, REGINA, JONAS, BRIAN A, BORTHAKUR, GAUTAM, ALDOSS, IBRAHIM, RIZZIERI, DAVID A, ODENIKE, OLATOYOSI, PREBET, THOMAS, SINGH, SANJANA, POPOVIC, RELJA, SHEN, YU, MCDANIEL, KEITH F, KATI, WARREN M, MODI, DIMPLE A, MOTWANI, MONICA, WOLFF, JOHANNES E, and FROST, DAVID J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Cancer, Hematology, Rare Diseases, Pediatric, Pediatric Research Initiative, Orphan Drug, Childhood Leukemia, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Animals, Cell Line, Tumor, Humans, Leukemia, Myeloid, Acute, Mice, Mice, Inbred NOD, Mice, SCID, Pyridones, Sulfonamides, Key Words, Mivebresib, co-clinical PDX models, BRT inhibitors, AML, Oncology & Carcinogenesis, Clinical sciences, Dentistry, Oncology and carcinogenesis
Abstract

Background/aimThe therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting agent has achieved approval. To add insight into potential response to mivebresib (ABBV-075), a broadspectrum BET inhibitor, co-clinical modeling of individual patient biopsies was conducted in the context of a Phase I trial in acute myeloid leukemia (AML).Materials and methodsCo-clinical modeling involves taking the patient's biopsy and implanting it in mice with limited passage so that it closely retains the original characteristics of the malignancy and allows comparisons of response between animal model and clinical data. Procedures were developed, initially with neonate NOD/Shi-scid-IL2rγnull (NOG) mice and then optimized with juvenile NOG-EXL as host mice, eventually resulting in a robust rate of engraftment (16 out of 26, 62%).ResultsResults from the co-clinical AML patient-derived xenograft (PDX) modeling (6 with >60% inhibition of bone marrow blasts) were consistent with the equivalent clinical data from patients receiving mivebresib in monotherapy, and in combination with venetoclax. The modeling system also demonstrated the activity of a novel BD2-selective BET inhibitor (ABBV-744) in the preclinical AML setting. Both agents were also highly effective in inhibiting blast counts in the spleen (10/10 and 5/6 models, respectively).ConclusionThese findings confirm the validity of the model system in the co-clinical setting, establish highly relevant in vivo models for the discovery of cancer therapy, and indicate the therapeutic value of BET inhibitors for AML and, potentially, myelofibrosis treatment.

Published
2022

8. A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Author

Borthakur, Gautam, Odenike, Olatoyosi, Aldoss, Ibrahim, Rizzieri, David A, Prebet, Thomas, Chen, Chris, Popovic, Relja, Modi, Dimple A, Joshi, Rujuta H, Wolff, Johannes E, and Jonas, Brian A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pediatric Cancer, Childhood Leukemia, Rare Diseases, Pediatric, Cancer, Genetics, Clinical Research, Hematology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Myeloid, Acute, Pyridones, Sulfonamides, ABBV&#8208, 075, acute myeloid leukemia, bromodomain and extraterminal domain protein, mivebresib, phase 1 clinical trial, ABBV-075, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundAcute myeloid leukemia (AML) is a heterogenous malignancy driven by genetic and epigenetic factors. Inhibition of bromodomain and extraterminal (BET) proteins, epigenetic readers that play pivotal roles in the regulation of genes relevant to cancer pathogenesis, constitutes a novel AML treatment approach.MethodsIn this first-in-human study of the pan-BET inhibitor mivebresib as monotherapy (MIV-mono) or in combination with venetoclax (MIV-Ven), the safety profile, efficacy, and pharmacodynamics of mivebresib were determined in patients with relapsed/refractory AML (ClinicalTrials.gov identifier NCT02391480). Mivebresib was administered at 3 monotherapy dose levels (1.5, 2.0, or 2.5 mg) or in combination with venetoclax (400 or 800 mg).ResultsForty-four patients started treatment: of 19 who started MIV-mono, 5 went on to receive MIV-Ven combination therapy after disease progression and a washout period. Twenty-five patients started MIV-Ven, resulting in a total of 30 patients treated with the combination. The most common mivebresib-related treatment-emergent adverse events were dysgeusia (74%), decreased appetite (42%), and diarrhea (42%) in the MIV-mono group and decreased appetite (44%), vomiting (44%), and nausea (40%) in the MIV-Ven group. Serious adverse events occurred in 14 patients (74%) who received MIV-mono and in 22 patients (88%) who received MIV-Ven. In the MIV-mono group, responses were complete remission with incomplete blood count recovery in 1 patient and resistant disease in 15 patients. In the MIV-Ven group, responses were complete remission in 2 patients, partial remission in 2 patients, morphologic leukemia-free state in 2 patients, resistant disease in 12 patients, and aplasia in 1 patient. The pharmacodynamic effects of mivebresib were proportional to dose and drug exposure.ConclusionsMivebresib was tolerated and showed antileukemic effects as monotherapy and in combination with venetoclax in patients with relapsed/refractory AML.Lay summaryMivebresib is a novel drug that influences the way cancer cells read genetic information. Mivebresib was tested together with venetoclax in patients with acute myeloid leukemia after standard medicines failed and the disease returned, or when standard medicine was unavailable. Adverse effects were described for different drug doses, and the dose that is tolerable was determined. In some patients, their leukemia improved for some time. More studies are necessary to determine whether mivebresib can be used to treat acute myeloid leukemia.

Published
2021

9. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

10. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

11. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Author

Issa, Ghayas C., Aldoss, Ibrahim, DiPersio, John, Cuglievan, Branko, Stone, Richard, Arellano, Martha, Thirman, Michael J., Patel, Manish R., Dickens, David S., Shenoy, Shalini, Shukla, Neerav, Kantarjian, Hagop, Armstrong, Scott A., Perner, Florian, Perry, Jennifer A., Rosen, Galit, Bagley, Rebecca G., Meyers, Michael L., Ordentlich, Peter, Gu, Yu, Kumar, Vinit, Smith, Steven, McGeehan, Gerard M., and Stein, Eytan M.

Published
2023
Full Text
View/download PDF

13. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

Author

Agrawal, Vaibhav, Pourhassan, Hoda, Tsai, Ni-Chun, Ngo, Dat, Koller, Paul, Malki, Monzr M. Al, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew, Singh, Dupinder, Becker, Pamela S., Stewart, Forrest M., Smith, Eileen P., Curtin, Peter, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Pullarkat, Vinod, and Aldoss, Ibrahim

Published
2023
Full Text
View/download PDF

14. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

16. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

Author

Arslan, Shukaib, Desai, Amrita, Yang, Dongyun, Mokhtari, Sally, Tiemann, Katrin, Otoukesh, Salman, Samara, Yazeed, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Aribi, Ahmed, Becker, Pamela, Curtin, Peter, Artz, Andrew, Aldoss, Ibrahim, Ali, Haris, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

17. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Author

Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C., Al Malki, Monzr, Aribi, Ahmed, Agrawal, Vaibhav, Sandhu, Karamjeet, Salhotra, Amandeep, Pourhassan, Hoda, Koller, Paul, Ali, Haris, Artz, Andrew, Karras, Nicole, Pawlowska, Anna B., Murphy, Lindsey, Palmer, Joycelynne, Stein, Anthony, Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Forman, Stephen J.

Published
2024
Full Text
View/download PDF

18. Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in myelofibrosis: Utility of 3D volumetrics in splenomegaly.

Author

Haseeb, Rafay, primary, Yang, Dongyun, additional, Motarjem, Pejman, additional, Al Malki, Monzr M., additional, Aldoss, Ibrahim, additional, Amanam, Idoroenyi Usua, additional, Otoukesh, Salman, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Rahmanuddin, Syed, additional, and Ali, Haris, additional

Published
2024
Full Text
View/download PDF

19. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.

Author

Jabbour, Elias, primary, Kantarjian, Hagop M., additional, Aldoss, Ibrahim, additional, Montesinos, Pau, additional, Leonard, Jessica Taft, additional, Gomez-Almaguer, David, additional, Baer, Maria R., additional, Gambacorti-Passerini, Carlo, additional, McCloskey, James K., additional, Minami, Yosuke, additional, Papayannidis, Cristina, additional, Rousselot, Philippe, additional, Vachhani, Pankit, additional, Wang, Eunice S., additional, Yang, Lin, additional, Hennessy, Meliessa, additional, Vorog, Alexander, additional, Patel, Niti, additional, and Ribera-Santasusana, Jose-Maria, additional

Published
2024
Full Text
View/download PDF

20. PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.

Author

Budde, Lihua Elizabeth, primary, Del Real, Marissa, additional, Baird, John H., additional, Chen, Lu, additional, Song, Joo Y, additional, Wang, Xiuli, additional, Kambhampati, Swetha, additional, Macias, Alan, additional, Kim, Teresa, additional, Dulan, Sylvia, additional, Barva, Baishakhi, additional, Guan, Min, additional, Espinosa, Ruby, additional, Puverel, Sandrine, additional, Tiemann, Katrin, additional, Cheng, Hazel (Ting-Ying), additional, Forman, Stephen J., additional, Kwak, Larry W., additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

21. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Author

Othman, Tamer, primary, Koller, Paul, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Tinajero, Jose, additional, Ali, Haris, additional, Cai, Ji‐Lian, additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

22. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia

Author

Othman, Tamer, primary, Li, Shanpeng, additional, Zhang, Jianying, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Chen, Jason, additional, Farol, Leonardo, additional, Sahebi, Firoozeh, additional, Sandhu, Karamjeet, additional, Spielberger, Ricardo, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, Nakamura, Ryotaro, additional, Pullarkat, Vinod, additional, Mei, Matthew, additional, Aldoss, Ibrahim, additional, and Koller, Paul, additional

Published
2024
Full Text
View/download PDF

23. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Author

Jabbour, Elias, primary, Kantarjian, Hagop M., additional, Aldoss, Ibrahim, additional, Montesinos, Pau, additional, Leonard, Jessica T., additional, Gómez-Almaguer, David, additional, Baer, Maria R., additional, Gambacorti-Passerini, Carlo, additional, McCloskey, James, additional, Minami, Yosuke, additional, Papayannidis, Cristina, additional, Rocha, Vanderson, additional, Rousselot, Philippe, additional, Vachhani, Pankit, additional, Wang, Eunice S., additional, Wang, Bingxia, additional, Hennessy, Meliessa, additional, Vorog, Alexander, additional, Patel, Niti, additional, Yeh, Tammie, additional, and Ribera, Jose-Maria, additional

Published
2024
Full Text
View/download PDF

24. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

25. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis

Author

Saygin, Caner, primary, Zhang, Pu, primary, Stauber, Jacob, primary, Aldoss, Ibrahim, primary, Sperling, Adam S., primary, Weeks, Lachelle D., primary, Luskin, Marlise R., primary, Knepper, Todd C., primary, Wanjari, Pankhuri, primary, Wang, Peng, primary, Lager, Angela M., primary, Fitzpatrick, Carrie, primary, Segal, Jeremy P., primary, Gharghabi, Mehdi, primary, Gurbuxani, Sandeep, primary, Venkataraman, Girish, primary, Cheng, Jason X., primary, Eisfelder, Bart J., primary, Bohorquez, Oliver, primary, Patel, Anand A., primary, Umesh Nagalakshmi, Sheethal, primary, Jayaram, Savita, primary, Odenike, Olatoyosi M., primary, Larson, Richard A., primary, Godley, Lucy A., primary, Arber, Daniel A., primary, Gibson, Christopher J., primary, Munshi, Nikhil C., primary, Marcucci, Guido, primary, Ebert, Benjamin L., primary, Greally, John M., primary, Steidl, Ulrich, primary, Lapalombella, Rosa, primary, Shah, Bijal D., primary, and Stock, Wendy, primary

Published
2024
Full Text
View/download PDF

26. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Author

Ghobadi, Armin, Slade, Michael, Kantarjian, Hagop, Alvarenga, Julio, Aldoss, Ibrahim, Mohammed, Kahee A., Jabbour, Elias, Faramand, Rawan, Shah, Bijal, Locke, Frederick, Fingrut, Warren, Park, Jae H., Short, Nicholas J., Gao, Feng, Uy, Geoffrey L., Westervelt, Peter, DiPersio, John F., Champlin, Richard E., Al Malki, Monzr M., Ravandi, Farhad, and Kebriaei, Partow

Published
2022
Full Text
View/download PDF

29. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Author

Aldoss, Ibrahim, Yang, Dongyun, Tomasian, Vanina, Mokhtari, Sally, Jackson, Ryan, Gu, Zhaohui, Telatar, Milhan, Yew, Hooi, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Mei, Matthew, Arslan, Shukaib, Koller, Paul, Artz, Andrew, Aoun, Patricia, Gu, Dongqing, Snyder, David, Stewart, Forrest M., Curtin, Peter, Stein, Anthony S., Pillai, Raju, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Nakamura, Ryotaro, and Afkhami, Michelle

Published
2022
Full Text
View/download PDF

31. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Author

Kimura, Shunsuke, Montefiori, Lindsey, Iacobucci, Ilaria, Zhao, Yaqi, Gao, Qingsong, Paietta, Elisabeth M., Haferlach, Claudia, Laird, A. Douglas, Mead, Paul E., Gu, Zhaohui, Stock, Wendy, Litzow, Mark, Rowe, Jacob M., Luger, Selina M., Hunger, Stephen P., Ryland, Georgina L., Schmidt, Breon, Ekert, Paul G., Oshlack, Alicia, Grimmond, Sean M., Rehn, Jacqueline, Breen, James, Yeung, David, White, Deborah L., Aldoss, Ibrahim, Jabbour, Elias J., Pui, Ching-Hon, Meggendorfer, Manja, Walter, Wencke, Kern, Wolfgang, Haferlach, Torsten, Brady, Samuel, Zhang, Jinghui, Roberts, Kathryn G., Blombery, Piers, and Mullighan, Charles G.

Published
2022
Full Text
View/download PDF

34. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Author

Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., and Nakamura, Ryotaro

Published
2022
Full Text
View/download PDF

35. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.

Author

Aldoss, Ibrahim, Zhang, Jianying, Robbins, Marjorie, Song, Joo, Al Malki, Monzr M., Otoukesh, Salman, Sandhu, Karamjeet, Agrawal, Vaibhav, Herrera, Alex F., Popplewell, Leslie L., Ghoda, Lucy, Stein, Anthony, Marcucci, Guido, Forman, Stephen, and Pullarkat, Vinod

Subjects
*HEMATOLOGIC malignancies, *HODGKIN'S disease, *CYTOKINE release syndrome, *IMMUNOTHERAPY, *CANCER remission
Abstract

CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor. Two dose limiting toxicities (Grade 4 thrombocytopenia and neutropenia) occurred in one patient in Cohort B. Cytokine release syndrome occurred in most patients (85%), all being grade ≤2. Responses only occurred in Cohort B, with a partial response in one patient with Hodgkin's lymphoma and morphological complete remission in the bone marrow in one patient with blastic plasmacytoid dendritic cell neoplasm. In conclusion, flotetuzumab had a manageable safety profile in advanced CD123-positive hematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study.

Author

Bewersdorf, Jan Philipp, Shimony, Shai, Shallis, Rory M., Liu, Yiwen, Berton, Guillaume, Schaefer, Eva J., Zeidan, Amer M., Goldberg, Aaron, Stein, Eytan, Marcucci, Guido, Bystrom, Rebecca P., Lindsley, R. Coleman, Chen, Evan C., Ramos, Jorge, Stein, Anthony, Pullarkat, Vinod, Aldoss, Ibrahim, DeAngelo, Daniel J., Neuberg, Donna S., and Stone, Richard M.

Published
2024
Full Text
View/download PDF

38. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Author

Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H, Sandmaier, Brenda, Horowitz, Mary, Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard, Gale, Robert, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew, Pulsipher, Michael, Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David

Subjects
Acute lymphoblastic leukemia, Allogeneic transplant, Busulfan, Total body irradiation, Administration, Intravenous, Adolescent, Adult, Allografts, Busulfan, Disease-Free Survival, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Survival Rate, Transplantation Conditioning, Whole-Body Irradiation
Abstract

Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors. With median follow-up of 3.6 years for Bu and 5.3 years for TBI, adjusted 3-year outcomes showed treatment-related mortality Bu 19% versus TBI 25% (P = .04); relapse Bu 37% versus TBI 28% (P = .007); disease-free survival (DFS) Bu 45% versus TBI 48% (P = .35); and overall survival (OS) Bu 57% versus TBI 53% (P = .35). In multivariate analysis, Bu patients had higher risk of relapse (relative risk, 1.46; 95% confidence interval, 1.15 to 1.85; P = .002) compared with TBI patients. Despite the higher relapse, Bu-containing conditioning led to similar OS and DFS following HCT for ALL.

Published
2018

41. Data from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development

Author

Goldberg, Lior, primary, Haas, Eric R., primary, Urak, Ryan, primary, Vyas, Vibhuti, primary, Pathak, Khyatiben V., primary, Garcia-Mansfield, Krystine, primary, Pirrotte, Patrick, primary, Singhal, Jyotsana, primary, Figarola, James L., primary, Aldoss, Ibrahim, primary, Forman, Stephen J., primary, and Wang, Xiuli, primary

Published
2024
Full Text
View/download PDF

42. Figure S4 from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development

Author

Goldberg, Lior, primary, Haas, Eric R., primary, Urak, Ryan, primary, Vyas, Vibhuti, primary, Pathak, Khyatiben V., primary, Garcia-Mansfield, Krystine, primary, Pirrotte, Patrick, primary, Singhal, Jyotsana, primary, Figarola, James L., primary, Aldoss, Ibrahim, primary, Forman, Stephen J., primary, and Wang, Xiuli, primary

Published
2024
Full Text
View/download PDF

43. Table S2 from Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development

Author

Goldberg, Lior, primary, Haas, Eric R., primary, Urak, Ryan, primary, Vyas, Vibhuti, primary, Pathak, Khyatiben V., primary, Garcia-Mansfield, Krystine, primary, Pirrotte, Patrick, primary, Singhal, Jyotsana, primary, Figarola, James L., primary, Aldoss, Ibrahim, primary, Forman, Stephen J., primary, and Wang, Xiuli, primary

Published
2024
Full Text
View/download PDF

44. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer

Author

Pourhassan, Hoda, primary, Zhang, Jianying, additional, Tinajero, Jose, additional, Pullarkat, Vinod, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Al Malki, Monzr, additional, Aribi, Ahmed, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Ali, Haris, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

45. A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant

Author

Nakamura, Ryotaro, primary, La Rosa, Corinna, additional, Yang, Dongyun, additional, Hill, Joshua A., additional, Rashidi, Armin, additional, Choe, Hannah, additional, Zhou, Qiao, additional, Lingaraju, Chetan Raj, additional, Kaltcheva, Teodora, additional, Longmate, Jeffrey, additional, Drake, Jennifer, additional, Slape, Cynthia, additional, Duarte, Lupe, additional, Al Malki, Monzr M., additional, Pullarkat, Vinod A., additional, Aribi, Ahmed, additional, Devine, Steven, additional, Verneris, Michael R., additional, Miller, Jeffrey S., additional, Forman, Stephen J., additional, Aldoss, Ibrahim, additional, and Diamond, Don J., additional

Published
2024
Full Text
View/download PDF

46. Immunometabolic Adaptation of CD19-Targeted CAR T Cells in the Central Nervous System Microenvironment of Patients Promotes Memory Development

Author

Goldberg, Lior, primary, Haas, Eric R., additional, Urak, Ryan, additional, Vyas, Vibhuti, additional, Pathak, Khyatiben V., additional, Garcia-Mansfield, Krystine, additional, Pirrotte, Patrick, additional, Singhal, Jyotsana, additional, Figarola, James L., additional, Aldoss, Ibrahim, additional, Forman, Stephen J., additional, and Wang, Xiuli, additional

Published
2024
Full Text
View/download PDF

47. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

48. Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Author

Ghobadi, Armin, primary, Aldoss, Ibrahim, additional, Maude, Shannon L., additional, Bhojwani, Deepa, additional, Wayne, Alan S., additional, Bajel, Ashish, additional, Bhagirathbhai, Dr. Dholaria, additional, Faramand, Rawan G, additional, Mattison, Ryan J., additional, Rettig, Michael P., additional, Jacobs, Kenneth, additional, Bakkacha, Ouiam, additional, Muth, John, additional, Pannunzio, Angela, additional, Ramsey, Brett, additional, McNulty, Eileen, additional, Cooper, Matthew, additional, Davidson-Moncada, Jan, additional, and DiPersio, John F., additional

Published
2024
Full Text
View/download PDF

49. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

Author

Samara, Yazeed, primary, Yao, Janny, additional, Tsai, Ni-Chun, additional, Mokhtari, Sally, additional, Aldoss, Ibrahim, additional, Ali, Haris, additional, Sandhu, Karamjeet S., additional, Salhotra, Amandeep, additional, Stein, Anthony S., additional, Arslan, Shukaib, additional, Aribi, Ahmed, additional, Borogovac, Azra, additional, Malki, Monzr M. Al, additional, Blackmon, Amanda, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Curtin, Peter, additional, Pourhassan, Hoda, additional, Koller, Paul, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Spielberger, Ricardo, additional, Becker, Pamela S., additional, Stewart, F. Marc, additional, Smith, Eileen, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

50. Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care

Author

Muhsen, Ibrahim N., primary, Roloff, Gregory, additional, Kopmar, Noam E., additional, Mercadal, Santiago, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Veeraputhiran, Muthu, additional, Mukherjee, Akash, additional, Logan, Aaron C., additional, Tsai, Dr. Stephanie B., additional, Leonard, Jessica T., additional, Schwartz, Marc, additional, Sasine, Joshua P, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Muffly, Lori S, additional, Hill, LaQuisa Chimere, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results